~~<i id='31189588B6'><strike id='31189588B6'><tt id='31189588B6'><pre id='31189588B6'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

explore

author：fashion 2025-09-06 04:26:45 - browse：9937

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Report: NIH

knowledge

focus

knowledge

focus

leisure time

hotspot

Advancesingenetherapycouldeventually"cure"manyformsofcongenitaldeafness.Thechangeshavemanydeafpeople

WSS

Insmed lung disease drug hits target in key Phase 3 trial

Childbirth

Scientists successfully use ultrasound imaging to map brain activity

Startling documents reveal new facets of Sacklers' opioid empire

Insmed lung disease drug hits target in key Phase 3 trial

Heat waves linked to early deliveries, preterm births in new study

leisure time

explore

knowledge

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Average age of first period drops to 11.9 years, study shows

Heart attack and stroke risk calculators need revising

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Guidelines to prevent youth baseball injuries need more muscle

Prosthetic arm enables patients to feel the objects they grip

Wildfire smoke exposes gaps in outdoor worker protections

Report: NIH

Dobbs anniversary: the lost opportunity of abortion as health care

MultiPlan and major insurers sued for alleged medical price

focus

Cell therapy fails to slow type 1 diabetes, but safety is established

Diversity in clinical trials starts with building trust, experts say

Childbirth

Dark money group runs ads on China biotech bill

Getting Alzheimer's drug Leqembi to patients can be a challenge

What will save rural psychiatry services? Higher Medicaid payments

knowledge

focus

leisure time

hotspot